Fulvestrant Versus Capecitabine as Maintenance Therapy After First-line Chemotherapy in Patients With HR+/HER2- Metastatic Breast Cancer
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Cai'wen Du, PhD
Chinese Academy of Medical Sciences
Principal Investigator - Herui Yao, PhD
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Study Chair - Kun Wang, PhD
Guangdong Provincial People's Hospital
Principal Investigator - Li Ling, PhD
Public Health Institute of Sun Yat-sen University
Principal Investigator - Mei Huang, MD
The First Affiliated Hospital, Guangzhou University of Traditional Chinese Medicine
Principal Investigator - Peijian Peng, PhD
Fifth Subsidiary Sun Yat-sen University Hospital
Principal Investigator - Quchang Ouyang, PhD
Hunan Cancer Hospital
Principal Investigator - Shusen Wang, PhD
Sun Yat-sen University
Principal Investigator - Ying Lin, phD
First Affiliated Hospital, Sun Yat-Sen University
Principal Investigator - Ying Zhang, MD
Affiliated Hospital of Guangdong Medical University
Principal Investigator - Yongkui Lu, MD
Affiliated Cancer Hospital of Guangxi Medical University
Principal Investigator - Zhiyong Wu, MD
Shantou Central Hospitalv
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
13 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Guangdong Provincial People'S Hospital
Guangzhou, Guangdong, China
Kun Wang, PhDRecruiting - Public Health Institute of Sun Yat-Sen University
Guangzhou, Guangdong, China
Recruiting - Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University
Guangzhou, Guangdong, China
Herui Yao, PhDRecruiting - Sun Yat-Sen University Cancer Center
Guangzhou, Guangdong, China
Shusen Wang, PhDRecruiting - the First Affiliated Hospital of Guangzhou University of Chinese Medicine
Guangzhou, Guangdong, China
Recruiting - the First Affiliated Hospital of Sun Yat-Sen University
Guangzhou, Guangdong, China
Recruiting - Shantou Central Hospital
Shantou, Guangdong, China
Recruiting - Cancer Hospital, Chinese Academy of Medical Sciences, Shenzhen Center
Shenzhen, Guangdong, China
Recruiting - Shenzhen People'S Hospital
Shenzhen, Guangdong, China
Not, yet, recruiting - Affiliated Hospital of Guangdong Medical University
Zhangjiang, Guangdong, China
Recruiting - Fifth Subsidiary Sun Yat-Sen University Hospital
Zhuhai, Guangdong, China
Recruiting - Affiliated Cancer Hospital of Guangxi Medical University
Nanning, Guangxi, China
Recruiting - Hunan Cancer Hospital
Changsha, Hunan, China
Recruiting
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 1 May 2018
- Primary completion
- 1 May 2025
- Completion
- 1 May 2030
- Last update posted
- 30 Sept 2022
- Registered enrollment
- 210
- Registry id
- NCT04263298
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.